<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732862</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#8842-NIDDM</org_study_id>
    <nct_id>NCT00732862</nct_id>
  </id_info>
  <brief_title>Metabolic Adaptation to Diabetes</brief_title>
  <official_title>Metabolic Adaptation to Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoglycemia or low blood sugar is a very serious complication that diabetics experience.&#xD;
      This is of great concern because there is a lack of available information of how Non Insulin&#xD;
      Dependent Diabetic Mellitus patients (NIDDM) defend themselves against a low blood sugar.&#xD;
      This is particularly disturbing since NIDDM patients are likely to require intensive&#xD;
      treatment, and as a result, the risks of severe hypoglycemia to the NIDDM patient increase.&#xD;
      The current proposal aims to provide information on how NIDDM patients can defend themselves&#xD;
      against hypoglycemia, thus decreasing their risks for this severe complication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is very little data available on the neuroendocrine response to hypoglycemia in&#xD;
      intensively treated (sulfonylurea or insulin) NIDDM patients. The data that are available on&#xD;
      the neuroendocrine response to hypoglycemia in NIDDM patients were obtained under conditions&#xD;
      following a single IV bolus of insulin or single SQ regular insulin injection. The&#xD;
      neuroendocrine response following a large IV bolus of insulin differs greatly from the&#xD;
      clinical paradigm of a slow progression into hypoglycemia. Therefore, clinically relevant&#xD;
      data cannot be obtained from short experiments involving rapid changes in plasma glucose&#xD;
      levels and insulinemia. Furthermore, a comparison between neuroendocrine responses to&#xD;
      hypoglycemia in NIDDM and normal man is not available due to the fact that glycemia has never&#xD;
      been equally controlled. In short, virtually nothing is known about the neuroendocrine&#xD;
      response to hypoglycemia in these subjects. This is of great concern as following the&#xD;
      positive outcome of the Kumamato study, large numbers of NIDDM subjects are going to receive&#xD;
      intensive therapy with all its altendent risks of severe hypoglycemia. The Kumamato study was&#xD;
      a trial in NIDDM patients to determine if intensive therapy reduces tissue complications of&#xD;
      diabetes. Similar to the results of the Diabetes control and complications trial in IDDM&#xD;
      patients the Kumamato study proved that intensive therapy in NIDDM patients also prevents&#xD;
      diabetic tissue complications. Therefore, the goals of this study are 1) to define in greater&#xD;
      detail how the body defends itself against hypoglycemia in NIDDM patients and 2) to determine&#xD;
      if differing levels of insulin affect hypoglycemic counterregulation in NIDDM patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1998</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">March 2000</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catecholamines</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline clamp study before treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Final clamp experiment after 6 months intensive therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>glucose clamp</intervention_name>
    <description>Hyperinsulinemic Hypoglycemic clamp</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>glucose clamp</intervention_name>
    <description>Hyperinsulinemic Hypoglycemic clamp</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects aged 30-65 years&#xD;
&#xD;
          -  Male and female non-insulin-dependent diabetic patients, sulfonylurea and/or Metformin&#xD;
             aged 30-65 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or current history of poor health&#xD;
&#xD;
          -  Abnormal results following screening tests&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen N Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <last_update_submitted>December 10, 2014</last_update_submitted>
  <last_update_submitted_qc>December 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Steve Davis</investigator_full_name>
    <investigator_title>Chairman of Medicine, University of Maryland, Baltimore</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>intensive therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

